1. Home
  2. ACRS vs GTE Comparison

ACRS vs GTE Comparison

Compare ACRS & GTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACRS
  • GTE
  • Stock Information
  • Founded
  • ACRS 2012
  • GTE 2003
  • Country
  • ACRS United States
  • GTE Canada
  • Employees
  • ACRS N/A
  • GTE N/A
  • Industry
  • ACRS Biotechnology: Pharmaceutical Preparations
  • GTE Oil & Gas Production
  • Sector
  • ACRS Health Care
  • GTE Energy
  • Exchange
  • ACRS Nasdaq
  • GTE Nasdaq
  • Market Cap
  • ACRS 165.7M
  • GTE 178.8M
  • IPO Year
  • ACRS 2015
  • GTE N/A
  • Fundamental
  • Price
  • ACRS $1.59
  • GTE $4.60
  • Analyst Decision
  • ACRS Strong Buy
  • GTE
  • Analyst Count
  • ACRS 9
  • GTE 0
  • Target Price
  • ACRS $9.25
  • GTE N/A
  • AVG Volume (30 Days)
  • ACRS 1.3M
  • GTE 347.8K
  • Earning Date
  • ACRS 08-06-2025
  • GTE 07-30-2025
  • Dividend Yield
  • ACRS N/A
  • GTE N/A
  • EPS Growth
  • ACRS N/A
  • GTE N/A
  • EPS
  • ACRS N/A
  • GTE N/A
  • Revenue
  • ACRS $17,777,000.00
  • GTE $634,805,000.00
  • Revenue This Year
  • ACRS N/A
  • GTE $11.42
  • Revenue Next Year
  • ACRS $11.77
  • GTE N/A
  • P/E Ratio
  • ACRS N/A
  • GTE N/A
  • Revenue Growth
  • ACRS N/A
  • GTE N/A
  • 52 Week Low
  • ACRS $1.05
  • GTE $3.34
  • 52 Week High
  • ACRS $5.17
  • GTE $10.35
  • Technical
  • Relative Strength Index (RSI)
  • ACRS 59.88
  • GTE 43.38
  • Support Level
  • ACRS $1.44
  • GTE $4.74
  • Resistance Level
  • ACRS $1.52
  • GTE $5.01
  • Average True Range (ATR)
  • ACRS 0.10
  • GTE 0.24
  • MACD
  • ACRS 0.00
  • GTE -0.06
  • Stochastic Oscillator
  • ACRS 79.17
  • GTE 6.52

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

About GTE Gran Tierra Energy Inc.

Gran Tierra Energy Inc is an independent energy company. The company, along with its subsidiaries, is focused on oil and gas exploration and production, with assets in Colombia, Canada, and Ecuador. It produces oil, natural gas, and natural gas liquids. Gran Tierra has assembled a diversified, high-quality asset base that is fully operated in Colombia and Ecuador and partly in Canada. The company operates various blocks in Colombia and Ecuador, spanning three basins. It also has contiguous areas in Alberta, Canada, spanning various gross acres across the Western Canadian Sedimentary Basin. The company's reportable segments are Colombia, Ecuador, Canada, and Other. A majority of its revenue is derived from its operations in Colombia.

Share on Social Networks: